ClinicalTrials.gg
CompletedNCT04386876OrvicalUpdated Dec 31, 2020

Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions

A Phase 1 interventional study of Lopinavir/Ritonavir 200 mg/50 mg Film Tablet and Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet in Bioequivalence, sponsored by World Medicine ILAC SAN. ve TIC. A.S.. Completed at 2 sites in Turkey. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by World Medicine ILAC SAN. ve TIC. A.S. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

A single dose of Reference product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination and a single dose of Test product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions.

Read the detailed description

The subjects will me isolated at the dorm during 5 days before the dosing.

02

Conditions studied

  • Bioequivalence

Keywords

  • COVID-19 drug treatment
  • Ritonavir
  • Lopinavir
  • Antiviral Agents
  • Kaletra
  • Novagenix
  • Farmagen
03

In context

Lead sponsor

World Medicine ILAC SAN. ve TIC. A.S. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Caucasian male subjects aged between 20 and 40 years,
  2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during the study period,
  3. Negative Covid-19 Rapid Test results and two Negative Covid-19 PCR test results,
  4. Negative alcohol breath test results,
  5. Normal physical examination at screening visit,
  6. Having the ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age,
  7. Ability to communicate adequately with the investigator himself or his representatives,
  8. Ability and agreement to comply with the study requirements,
  9. Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,
  10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest,
  11. Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated (eGFR), total , sodium, potassium, calcium, chloride, (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),
  12. Understanding of the study and agreement to give a written according to section 20.3.
  13. Volunteer's compliance with isolation rules defined at study protocol

Exclusion criteria

Exclusion Criteria:

  1. Who have atopic constitution or asthma or known allergy for lopinavir and ritonavir or any other ingredients of the products.
  2. Any history or presence of clinical relevance of cardiovascular (myocardial infarction/ ischaemia and/or etc.), neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria.
  3. Baseline should be performed at screening. Exclude subjects having a QTc > 440 ms
  4. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator),
  5. Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
  6. Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration.
  7. Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement.
  8. Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product).
  9. Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
  10. Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug.
  11. Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day.
  12. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study.
  13. History of allergic response to heparin.
  14. History of drug abuse.
  15. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).
  16. Positive blood test for , and .
  17. Who have relationship to the investigator.
  18. Who are not suitable to any of inclusion criteria.
  19. History of difficulty of swallowing.
  20. Intake of depot injectable solutions (including study medications) within 6 months before start of the study.
  21. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study.
  22. Special diet due to any reason, e.g. vegetarian.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Orvical-Kaletra-Orvical-Kaletra

    In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH \& Co.-Germany. All periods were performed under fasting state.

    Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet · Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet

  • Experimental
    Kaletra-Orvical-Kaletra-Orvical

    In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH \& Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.

    Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet · Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet

Interventions

  • DrugLopinavir/Ritonavir 200 mg/50 mg Film Tablet

    Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).

    Also known as: Orvical 200 mg/50 mg Film Tablet

  • DrugLopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet

    Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)

    Also known as: Kaletra 200 mg/50 mg Film Coated Tablet

06

What researchers measure

Primary outcomes

  1. Primary PK End Points

    AUC0-tlast of lopinavir and ritonavir

    Time frame: 12 weeks

  2. Primary PK End Points

    Cmax of lopinavir and ritonavir

    Time frame: 13 weeks

07

Study locations

2 sites
  • Novagenix Drug R&D Center
    Akyurt, Ankara 06970, Turkey
  • Farmagen Ar-Ge Biyot. Ltd. Sti.
    Sahinbey, Gaziantep 27000, Turkey
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in May 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2020
First posted
May 13, 2020
StartActual
Apr 30, 2020
Primary completionActual
May 22, 2020
CompletionActual
Jun 11, 2020
Last update
Dec 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04386876
Lead sponsor
World Medicine ILAC SAN. ve TIC. A.S.
Collaborators
Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti
Responsible party
Sponsor
First posted
May 13, 2020
Start date
Apr 30, 2020
Primary completion
May 22, 2020
Completion
Jun 11, 2020
Last update
Dec 31, 2020

Study contacts

Muradiye Nacak, MD,PhD
principal investigator · Farmagen Ar-Ge Biyot. Ltd. Sti

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion